HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -6.01 Billion KRW | -111.73% |
| 2022 | 51.25 Billion KRW | 399.59% |
| 2021 | 10.25 Billion KRW | 948.17% |
| 2020 | 978.83 Million KRW | -66.83% |
| 2019 | 2.95 Billion KRW | -52.65% |
| 2018 | 6.23 Billion KRW | 240.71% |
| 2017 | 1.82 Billion KRW | -54.73% |
| 2016 | 4.04 Billion KRW | -28.93% |
| 2015 | 5.68 Billion KRW | -3.96% |
| 2014 | 5.92 Billion KRW | 139.65% |
| 2013 | 2.47 Billion KRW | -64.49% |
| 2012 | 6.95 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.26 Billion KRW | 125.7% |
| 2024 Q1 | 1 Billion KRW | 153.61% |
| 2023 Q4 | -1.87 Billion KRW | -51.4% |
| 2023 Q2 | -5.63 Billion KRW | -949.03% |
| 2023 Q1 | 663.45 Million KRW | -89.6% |
| 2023 Q3 | -1.23 Billion KRW | 78.07% |
| 2023 FY | -6.01 Billion KRW | -111.73% |
| 2022 Q3 | 2.32 Billion KRW | -88.52% |
| 2022 Q4 | 6.38 Billion KRW | 174.83% |
| 2022 Q2 | 20.21 Billion KRW | -9.49% |
| 2022 Q1 | 22.33 Billion KRW | 42.13% |
| 2022 FY | 51.25 Billion KRW | 399.59% |
| 2021 Q2 | -4.61 Billion KRW | -5479.38% |
| 2021 Q4 | 15.71 Billion KRW | 2165.32% |
| 2021 Q3 | -760.94 Million KRW | 83.5% |
| 2021 FY | 10.25 Billion KRW | 948.17% |
| 2021 Q1 | -82.67 Million KRW | -102.03% |
| 2020 Q4 | 4.07 Billion KRW | 173.71% |
| 2020 FY | 978.83 Million KRW | -66.83% |
| 2020 Q2 | 2.16 Billion KRW | -13.52% |
| 2020 Q1 | 2.5 Billion KRW | 596.23% |
| 2020 Q3 | 1.48 Billion KRW | -31.29% |
| 2019 Q2 | 1.89 Billion KRW | 62.48% |
| 2019 FY | 2.95 Billion KRW | -52.65% |
| 2019 Q4 | -504.53 Million KRW | -137.77% |
| 2019 Q3 | 1.33 Billion KRW | -29.38% |
| 2019 Q1 | 1.16 Billion KRW | -31.9% |
| 2018 Q4 | 1.7 Billion KRW | 25.38% |
| 2018 FY | 6.23 Billion KRW | 240.71% |
| 2018 Q2 | 2.34 Billion KRW | 131.65% |
| 2018 Q1 | 1.01 Billion KRW | 226.53% |
| 2018 Q3 | 1.36 Billion KRW | -41.82% |
| 2017 Q1 | 1.3 Billion KRW | 894.74% |
| 2017 FY | 1.82 Billion KRW | -54.73% |
| 2017 Q4 | -799.62 Million KRW | -247.06% |
| 2017 Q3 | 543.72 Million KRW | -47.34% |
| 2017 Q2 | 1.03 Billion KRW | -20.94% |
| 2016 FY | 4.04 Billion KRW | -28.93% |
| 2016 Q4 | 131.28 Million KRW | -75.23% |
| 2016 Q3 | 530.11 Million KRW | -59.33% |
| 2016 Q2 | 1.3 Billion KRW | -41.19% |
| 2016 Q1 | 2.21 Billion KRW | 51.46% |
| 2015 Q1 | 1.56 Billion KRW | 9.81% |
| 2015 Q4 | 1.46 Billion KRW | -20.17% |
| 2015 Q3 | 1.83 Billion KRW | 66.72% |
| 2015 Q2 | 1.09 Billion KRW | -29.96% |
| 2015 FY | 5.68 Billion KRW | -3.96% |
| 2014 Q2 | 1.18 Billion KRW | -12.14% |
| 2014 Q4 | 1.42 Billion KRW | -26.79% |
| 2014 Q1 | 1.35 Billion KRW | 113.79% |
| 2014 FY | 5.92 Billion KRW | 139.65% |
| 2014 Q3 | 1.95 Billion KRW | 64.5% |
| 2013 Q1 | 864.54 Million KRW | 416.39% |
| 2013 Q3 | 401.03 Million KRW | -73.01% |
| 2013 FY | 2.47 Billion KRW | -64.49% |
| 2013 Q4 | -9.79 Billion KRW | -2543.26% |
| 2013 Q2 | 1.48 Billion KRW | 71.84% |
| 2012 Q4 | 167.42 Million KRW | -89.8% |
| 2012 FY | 6.95 Billion KRW | 0.0% |
| 2012 Q3 | 1.64 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | 231.827% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 110.612% |
| Bioneer Corporation | 199.25 Billion KRW | 103.018% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | 371.635% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 114.962% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | 512.66% |
| Helixmith Co., Ltd | 2.12 Billion KRW | 383.36% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 102.356% |
| Medy-Tox Inc. | 128.16 Billion KRW | 104.691% |
| Peptron, Inc. | 1.14 Billion KRW | 627.143% |
| Amicogen, Inc. | 51.51 Billion KRW | 111.672% |
| Genexine, Inc. | 387.48 Million KRW | 1651.668% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 189.816% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 133.783% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 119.272% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 103.299% |
| SillaJen, Inc. | 1.45 Billion KRW | 512.734% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 122.619% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 141.689% |
| Genomictree Inc. | -1.03 Billion KRW | -478.906% |
| MedPacto, Inc. | -1.83 Billion KRW | -228.073% |
| D&D Pharmatech | 18.67 Billion KRW | 132.192% |
| EASY BIO,Inc. | 50.88 Billion KRW | 111.816% |
| GI Innovation, Inc. | 1.98 Billion KRW | 402.222% |